Clinical Trial for ANCA-Associated Vasculitis – Now Enrolling Patients
Sites throughout the U.S. and Canada are seeking patients with newly diagnosed or relapsed anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This clinical trial is designed to determine whether a new non-steroidal treatment, when added to standard of care treatment can improve the remission rate, kidney function, and/or improve vasculitis symptoms. All…...
RITAZAREM Trial – Now Enrolling Patients
The RITAZAREM Trial is an international, open label, randomized controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis. Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its effect…...
